ArticlePharmaceutics2026

Long-Term Survival Heterogeneity Across PD-L1-Defined Subgroups in Pembrolizumab-Treated Non-Small-Cell Lung Cancer: A Model-Based Analysis.

Heungjo Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.